Nalaganje...
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive da...
Shranjeno v:
| izdano v: | Front Neurol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439479/ https://ncbi.nlm.nih.gov/pubmed/30967831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.00253 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|